Effective Management of Diabetes in Arab Region: Insights and Strategies

By Melike Belenli Gümüş

November 14, 2024

Introduction

Diabetes prevalence in the Arab region has surged, placing a heavy economic strain on healthcare systems. This increase is largely due to factors such as obesity, rapid urbanisation, and sedentary lifestyles. Effective diabetes management is crucial for maintaining optimal health and preventing complications. An expert consensus statement from Arab Diabetes Forum (ADF) has established key strategies, including preoperative risk assessment, obesity management, and fasting guidelines during Ramadan. By understanding these approaches, individuals can better manage their condition and improve their quality of life.

Integration of Global Standards and Regional Data

The ADF, comprising endocrinologists from various Arab countries, has developed tailored recommendations to improve diabetes management and treatment quality across the region. Their guideline integrates global standards from organisations like the American Diabetes Association (ADA), International Society for Pediatric and Adolescent Diabetes (ISPAD), American Association of Clinical Endocrinology (AACE), National Institute for Health and Care Excellence (NICE), and International Diabetes Federation (IDF), along with regional data. It emphasises evidence-based recommendations and was formulated through collaborative discussions with specialists, including pharmacists and dietitians.

Preoperative Risk Assessment

Before elective surgeries, a thorough preoperative risk assessment is essential for individuals with diabetes. This is particularly important for those at high risk of ischemic heart disease, autonomous neuropathy, or renal failure. The target HbA1c level should be below 8%, and blood glucose should range between 100–180 mg/dL within four hours of surgery. These measures help minimise surgical complications and promote faster recovery.

Obesity and Diabetes

Obesity significantly increases the risk of developing type 2 diabetes. In the Eastern Mediterranean Region, obesity prevalence is high, largely due to unhealthy diets. Managing obesity can delay the progression to type 2 diabetes and may even induce remission. A holistic approach, including physical activity, diet, behavioural therapy, and metabolic surgery, is recommended. This comprehensive strategy addresses the root causes of obesity and supports long-term health improvements.

Figure 1. Medication that should be avoided in diabetic patients.

Fasting During Ramadan

Many Muslims with diabetes choose to fast during Ramadan, despite religious permissions to abstain. Over the past 20 years, recommendations for fasting have evolved from expert opinions to evidence-based guidelines. It is crucial for individuals with diabetes to consult healthcare professionals before fasting. This ensures that their health is not compromised and that they can safely observe the fast.

Insulin Therapy for Children and Adolescents

Insulin therapy is vital for managing type 1 diabetes in children and adolescents. Rapid-acting insulins, such as Lispro, Aspart, and Glulisine, improve postprandial glucose control. These should be administered 10–15 minutes before meals to match food consumption and reduce hypoglycaemia risk. Basal insulin analogues provide consistent insulin release, preventing ketogenesis and hepatic glucose output. This tailored approach ensures effective diabetes management in young patients.

Conclusion

Effective diabetes management requires a multifaceted approach, including preoperative risk assessment, obesity management, and tailored insulin therapy. By following these strategies, individuals can better manage their condition and improve their overall health. For those observing Ramadan, consulting healthcare professionals is essential to ensure safe fasting practices. Therefore, the recommendations provided by the Arab Diabetes Forum are crucial for enhancing diabetes management in the region, as they integrate global best practices with local insights to improve treatment quality and patient outcomes.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.